Data / Drug companies / L'Oreal USA Products Inc
L'Oreal USA Products Inc: 220 products in the FDA NDC directory, labeler code 49967
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
L'Oreal USA Products Inc (labeler code 49967) lists 220 products in the FDA National Drug Code Directory, covering 35 finished drugs by generic name. By type: 220 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on November 15, 2025.
The request: Watch L'Oreal USA Products Inc (FDA labeler code 49967): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 49967
- Products in commercial distribution
- 220
- Packages
- 487
- Finished drugs by generic name
- 35
- Prescription products
- 0
- Over the counter products
- 220
- Flagged as original packager
- 220 of 220 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 3
- Earliest marketing start
- January 1, 2004
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 216 | 98.2% |
| Generic drugs (ANDA) | 4 | 1.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 220 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Avobenzone, homosalate, octisalate and octocrylene | 48 | 6 |
| Salicylic acid | 38 | 330 |
| Titanium dioxide and zinc oxide | 16 | 46 |
| Octinoxate | 11 | 10 |
| Avobenzone, octisalate and octocrylene | 10 | 4 |
| Octinoxate and titanium dioxide | 9 | 10 |
| Avobenzone, homosalate, octisalate, and octocrylene | 9 | 23 |
| Titanium dioxide | 9 | 51 |
| Pyrithione zinc | 8 | 76 |
| Homosalate, octisalate and octocrylene | 5 | 2 |
| Benzoyl peroxide | 4 | 82 |
| Oatmeal | 3 | 21 |
| Ensulizole | 3 | 4 |
| Adapalene | 3 | 34 |
| Petrolatum | 3 | 74 |
| Sulfur | 3 | 52 |
| Menthol | 2 | 263 |
| Dimethicone | 2 | 69 |
| Pramoxine hydrochloride | 2 | 15 |
| Homosalate, octisalate, octocrylene and zinc oxide | 2 | 1 |
| Aluminum chlorohydrate | 2 | 46 |
| Avobenzone, homosalate and octisalate | 1 | 1 |
| Octisalate and octocrylene | 1 | 1 |
| Minoxidil | 1 | 113 |
| Colloidal oatmeal | 1 | 66 |
| Homosalate, octisalate, octocrylene, and zinc oxide | 1 | 1 |
| Glycerin | 1 | 56 |
| Allantoin | 1 | 31 |
| Benzoyl peroxide and salicylic acid | 1 | 2 |
| Octinoxate and zinc oxide | 1 | 8 |
| Selenium sulfide, micronized | 1 | 2 |
| Hydrocortisone | 1 | 171 |
| Homosalate,octisalate and octocrylene | 1 | 1 |
| Avobenzone, homoslate, octisalate and octocrylene | 1 | 1 |
| Titanium dioxide, zinc oxide | 1 | 255 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Lotion | 100 | 45.5% |
| Cream | 52 | 23.6% |
| Liquid | 27 | 12.3% |
| Gel | 19 | 8.6% |
| Shampoo | 8 | 3.6% |
| Solution | 4 | 1.8% |
| Ointment | 3 | 1.4% |
| Lipstick | 2 | 0.9% |
| Oil | 1 | 0.5% |
| Kit | 1 | 0.5% |
| Paste | 1 | 0.5% |
| Spray | 1 | 0.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| KIEHLS SINCE 1851 Ultra Facial Meltdown Recovery | 49967-571 | Cream | Over the counter monograph drugs | November 15, 2025 |
| Cerave Developed with Dermatologists Healing | 49967-721 | Ointment | Over the counter monograph drugs | November 1, 2025 |
| CeraVe Developed with Dermatologists Skin Renewing Brightening with Sunscreen Broad Spectrum SPF 30 | 49967-360 | Lotion | Over the counter monograph drugs | October 1, 2025 |
| IT Cosmetics Your Skin But Better CC Plus Color Correcting Broad Spectrum SPF 50 Plus Sunscreen Full Coverage Deep Deep Honey Deep Bronze Neutral Deep Deep Mocha Tan Cool Rich Cool Deep Cool Neutral Rich | 49967-904 | Cream | Over the counter monograph drugs | August 1, 2025 |
| La Roche Posay Laboratoire Dermatologique Effaclar AZ Acne Treatment | 49967-735 | Cream | Over the counter monograph drugs | June 12, 2025 |
| Vichy Laboratoires Dercos Salicylic Acid Antidandruff Water to Foam | 49967-927 | Shampoo | Over the counter monograph drugs | June 1, 2025 |
| Youth to the People Youthscreen Sunscreen Broad Spectrum SPF 60 | 49967-169 | Cream | Over the counter monograph drugs | May 15, 2025 |
| La Roche Posay Laboratoire Dermatologique Effaclar Duo Plus M Multi Target Acne Treatment | 49967-926 | Liquid | Over the counter monograph drugs | May 14, 2025 |
| CeraVe Acne Clay-to-Foam Cleanser | 49967-600 | Gel | Over the counter monograph drugs | May 1, 2025 |
| LOreal Paris Revitalift Triple Power Anti Aging Moisturizer Broad Spectrum SPF 30 Sunscreen | 49967-341 | Cream | Over the counter monograph drugs | May 1, 2025 |
| Kiehls Gently Effective Acne Treating Cleansing | 49967-464 | Paste | Over the counter monograph drugs | January 7, 2025 |
| La roche posay laboratoire dermatologique toleraine double repair matte moisturizer uv broad spectrum spf 30 for oily, combination skin | 49967-387 | Cream | Over the counter monograph drugs | January 3, 2025 |
| La Roche Posay Laboratoire Dermatologique Effaclar Duo Dual Action Acne Medication Cleanser | 49967-647 | Liquid | Over the counter monograph drugs | January 1, 2025 |
| CeraVe Developed With Dermatologist Baby Eczema Relief Cream | 49967-536 | Cream | Over the counter monograph drugs | January 1, 2025 |
| Carols daughter hair regrowth treatment | 49967-988 | Solution | Generic drugs (ANDA) | December 16, 2024 |
| Dercos Salicylic Acid Anti-Dandruff Serum | 49967-892 | Liquid | Over the counter monograph drugs | November 5, 2024 |
| Lancome Paris UV Expert Supra Screen Invisible Sunscreen Serum Broad Spectrum SPF 50 | 49967-293 | Liquid | Over the counter monograph drugs | November 1, 2024 |
| CeraVe 2 in 1 Anti-Dandruff Hydrating Conditioner | 49967-266 | Shampoo | Over the counter monograph drugs | November 1, 2024 |
| CeraVe Anti-Dandruff Hydrating Conditioner | 49967-242 | Liquid | Over the counter monograph drugs | November 1, 2024 |
| La Roche Posay Anthelios UV Clear Daily Invisible Broad Spectrum SPF 50 Sunscreen | 49967-211 | Lotion | Over the counter monograph drugs | November 1, 2024 |
| VICHY LABORATOIRES DERCOS Selenium Sulfide Anti-Dandruff | 49967-974 | Shampoo | Over the counter monograph drugs | October 1, 2024 |
| CeraVe Facial Moisturizing with Sunscreen Broad Spectrum SPF 30 | 49967-346 | Lotion | Over the counter monograph drugs | September 19, 2024 |
| Effaclar | 49967-592 | Gel | Generic drugs (ANDA) | September 16, 2024 |
| LOreal Paris Infallible UP TO 32H Fresh Wear Foundation Broad Spectrum SPF 25 Sunscreen | 49967-815 | Liquid | Over the counter monograph drugs | September 1, 2024 |
| Cerave Hydrating Mineral Sunscreen Broad Spectrum SPF 30 Deep Sheer Tint | 49967-903 | Lotion | Over the counter monograph drugs | August 15, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.